# Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy Volunteers

> **NCT06552624** · NA · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 40 (actual)

## Conditions studied

- Heartburn
- Acid-dependent Diseases of the Gastrointestinal Tract
- Symptomatic Treatment of Gastric and Duodenal Ulcers

## Interventions

- **DRUG:** Magaldrate
- **DRUG:** Magaldrate

## Key facts

- **NCT ID:** NCT06552624
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-07
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06552624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06552624, "Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 800 mg Chewable Tablets in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06552624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*